Yemaachi Biotech

Targeted gene panel sequencing of liquid and tissue biopsies reveals actionable genomic alterations in Ghanaian metastatic breast cancer cases

Emmanuella Amoako abc, Setor Amuzu a, Emmanuel Owusu Ofori b, Harry Sefoga Akligoh a, Randy Tackie a, Barikisu Anna Ibrahim a, Emmanuel Kofi Quaye a, Patrick Kafui Akakpo bcd, Luke Adagrah Aniakwo b, Bashiro Jimah bc, Kofi Ulzen-Appiah bc, David Hutchful a, Aida Manu a, Joyce M Ngoi a, Lily Paemka a, Yakubu Alhassan ae, Ernest Amo Obeng d, Nicole Lim f, Lisa Rajah f, Michelle Pek f…Yaw Bediako a Abstract Purpose: Breast cancer is a major cause of cancer-related mortality among African women. The adoption of molecular genomic technologies in the management of cancer cases is limited in Africa. To provide much-needed insights on the feasibility and utility of such precision medicine paradigms in Africa, […]

Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines

Our research on the COURAGE cohort of our Heritage Study has been published in BMC Rheumatology! The COvid-19 vaccine immUne Response in Autoimmune rheumatic patients: a Ghanaian Experience (COURAGE) study, led by Dr. Ida Dzifa Dey, followed 38 patients with Systemic lupus erythematous (SLE) and Rheumatoid arthritis (RA) over 12 months at Korle-Bu Teaching Hospital, to access changes in clinical disease activity following COVID-19 vaccination, and to understand vaccine immune response in this subset.

Liquid Biopsy – The necessary first step towards democratising precision oncology?

While IHC and imaging are useful for diagnosing and staging cancers, they are limited in their ability to inform clinical decision-making regarding the use of increasingly available targeted therapies that are revolutionising cancer care in developed countries. For this, more advanced molecular tests are required, and next generation sequencing-based liquid biopsy tests are at the cutting edge.